These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 25631854)

  • 21. Significance of the expression of phosphorylated signal transducer and activator of transcription-3, -Akt, and -cyclin D1 in angiosarcoma.
    Lin N; Uchi H; Moroi Y; Fukiwake N; Dainichi T; Takeuchi S; Takahara M; Tu Y; Furue M; Urabe K
    J Dermatol Sci; 2007 Oct; 48(1):64-6. PubMed ID: 17720094
    [No Abstract]   [Full Text] [Related]  

  • 22. C-terminal AKT phosphorylation by CDK2-cyclin A or mTOR activates AKT.
    Cancer Discov; 2014 May; 4(5):OF19. PubMed ID: 24795023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5,3'-Dihydroxy-6,7,4'-trimethoxyflavanone exerts its anticancer and antiangiogenesis effects through regulation of the Akt/mTOR signaling pathway in human lung cancer cells.
    Kim KM; Heo DR; Lee J; Park JS; Baek MG; Yi JM; Kim H; Bang OS
    Chem Biol Interact; 2015 Jan; 225():32-9. PubMed ID: 25446852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cadherin attenuates insulin-dependent signalling, eNOS activation, and angiogenesis in vascular endothelial cells.
    Philippova M; Joshi MB; Pfaff D; Kyriakakis E; Maslova K; Erne P; Resink TJ
    Cardiovasc Res; 2012 Mar; 93(3):498-507. PubMed ID: 22235028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
    Bitting RL; Armstrong AJ
    Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy.
    Martelli AM; Tabellini G; Ricci F; Evangelisti C; Chiarini F; Bortul R; McCubrey JA; Manzoli FA
    Adv Biol Regul; 2012 Jan; 52(1):214-27. PubMed ID: 21983557
    [No Abstract]   [Full Text] [Related]  

  • 27. PLC and PI3K/Akt/mTOR signalling in disease and cancer.
    Follo MY; Manzoli L; Poli A; McCubrey JA; Cocco L
    Adv Biol Regul; 2015 Jan; 57():10-6. PubMed ID: 25482988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways.
    Jhanwar-Uniyal M; Albert L; McKenna E; Karsy M; Rajdev P; Braun A; Murali R
    Adv Enzyme Regul; 2011; 51(1):164-70. PubMed ID: 21035497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A group of novel HIF-1α inhibitors, glyceollins, blocks HIF-1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding.
    Lee SH; Jee JG; Bae JS; Liu KH; Lee YM
    J Cell Physiol; 2015 Apr; 230(4):853-62. PubMed ID: 25204544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
    Maira SM; Furet P; Stauffer F
    Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation.
    Nagai S; Kurebayashi Y; Koyasu S
    Ann N Y Acad Sci; 2013 Mar; 1280():30-4. PubMed ID: 23551100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling.
    Fulda S
    Mitochondrion; 2014 Nov; 19 Pt A():85-7. PubMed ID: 24780492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
    Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
    Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas.
    Monsalves E; Juraschka K; Tateno T; Agnihotri S; Asa SL; Ezzat S; Zadeh G
    Endocr Relat Cancer; 2014 Aug; 21(4):R331-44. PubMed ID: 25052915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [CA916798 gene participates in cisplatin resistance of human lung adenocarcinoma A549 cells through PI3K/AKT/mTOR pathway].
    Qi Z; Wang Y; Zhou X
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1290-3. PubMed ID: 22985566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical analysis of the Akt/mTOR/4E-BP1 signalling pathway in canine haemangiomas and haemangiosarcomas.
    Murai A; Abou Asa S; Kodama A; Sakai H; Hirata A; Yanai T
    J Comp Pathol; 2012 Nov; 147(4):430-40. PubMed ID: 22789858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
    Takahashi Y; Kohashi K; Yamada Y; Endo M; Setsu N; Ishii T; Yamamoto H; Iwamoto Y; Oda Y
    Hum Pathol; 2014 May; 45(5):984-93. PubMed ID: 24746202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome.
    Sartorelli S; De Luca G; Campochiaro C; Peretto G; Sala S; Esposito A; Busnardo E; Basso C; Thiene G; Dagna L
    Scand J Rheumatol; 2019 Nov; 48(6):515-516. PubMed ID: 30794015
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.